Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc. (CYTH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cyth · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cyclo Therapeutics, Inc. (CYTH) measures how much investors pay for each dollar of the company's trailing earnings. CYTH's current PE ratio of N/A is calculated by dividing its stock price of $0.72 by its TTM earnings per share of -$1.23.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2004 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%16.3x
MedianQ3 · 75%64.3x
Max
At N/A, CYTH's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cyclo Therapeutics, Inc.You CYTH | $24M | N/A | — | -$1.23 |
 Elevation Oncology, Inc. ELEV | $22M | N/A | — | -$0.78 |
 Elutia Inc. ELUT | $44M | 0.54x | — | $1.29 |
 HEXO Corp. HEXO | $31M | N/A | — | -$38.68 |
 Invacare Corporation IVC | $25M | N/A | — | -$2.77 |
 LakeShore Biopharma Co., Ltd LSB | $26M | N/A | — | -$0.94 |
 MEI Pharma, Inc. MEIP | $20M | N/A | — | -$2.39 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-1.23 | — | |
2022-12-31 FY2022 | — | $-1.81 | — | |
2021-12-31 FY2021 | — | $-2.25 | — | |
2020-12-31 FY2020 | — | $-5.58 | — | |
2019-12-31 FY2019 | — | $-7.09 | — | |
2018-12-31 FY2018 | — | $-5.20 | — | |
2017-12-31 FY2017 | — | $-5.32 | — | |
2016-12-31 FY2016 | — | $-6.67 | — | |
2015-12-31 FY2015 | — | $-4.54 | — | |
2014-12-31 FY2014 | — | $-1.17 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cyclo Therapeutics, Inc. (CYTH) measures how much investors pay for each dollar of the company's trailing earnings. CYTH's current PE ratio of N/A is calculated by dividing its stock price of $0.72 by its TTM earnings per share of -$1.23.
Frequently asked questions
CYTH pe ratio · 6 questionsCYTH's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.72 and TTM EPS of -$1.23. Data sourced from Financial Modeling Prep via CYTH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cyclo Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09